AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy
AbbVie is conducting Phase 2b/3 clinical trial to evaluate surabgene lomparvovec as a gene therapy for diabetic retinopathy.
Asset / Drug
Drug and asset intelligence for Surabgene Lomparvovec with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.